Andra AP fonden Acquires 79,400 Shares of Edwards Lifesciences Corporation $EW

Andra AP fonden lifted its stake in Edwards Lifesciences Corporation (NYSE:EW) by 6,616.7% during the third quarter, HoldingsChannel reports. The firm owned 80,600 shares of the medical research company’s stock after purchasing an additional 79,400 shares during the period. Andra AP fonden’s holdings in Edwards Lifesciences were worth $6,268,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its holdings in shares of Edwards Lifesciences by 7.0% in the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 137,835 shares of the medical research company’s stock valued at $10,719,000 after purchasing an additional 9,069 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in Edwards Lifesciences by 13.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,235 shares of the medical research company’s stock valued at $6,706,000 after purchasing an additional 10,078 shares in the last quarter. Arkadios Wealth Advisors purchased a new stake in shares of Edwards Lifesciences in the 2nd quarter worth $300,000. Atlantic Union Bankshares Corp grew its position in shares of Edwards Lifesciences by 2,240.9% during the 3rd quarter. Atlantic Union Bankshares Corp now owns 11,892 shares of the medical research company’s stock worth $925,000 after buying an additional 11,384 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp increased its stake in shares of Edwards Lifesciences by 97.3% during the second quarter. OMERS ADMINISTRATION Corp now owns 44,504 shares of the medical research company’s stock valued at $3,481,000 after buying an additional 21,950 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently weighed in on the company. UBS Group restated a “neutral” rating and issued a $94.00 price objective on shares of Edwards Lifesciences in a report on Wednesday, February 4th. Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday, January 21st. BTIG Research reiterated a “buy” rating and set a $103.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 11th. Stifel Nicolaus set a $110.00 price objective on shares of Edwards Lifesciences and gave the company a “buy” rating in a report on Tuesday, January 20th. Finally, Piper Sandler restated an “overweight” rating and set a $100.00 target price (up from $98.00) on shares of Edwards Lifesciences in a report on Wednesday, February 11th. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, Edwards Lifesciences presently has an average rating of “Moderate Buy” and a consensus price target of $96.14.

Insider Activity at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 24,000 shares of the business’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $83.84, for a total transaction of $2,012,160.00. Following the sale, the vice president owned 21,266 shares in the company, valued at approximately $1,782,941.44. The trade was a 53.02% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Daniel J. Lippis sold 1,019 shares of the company’s stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $85.70, for a total transaction of $87,328.30. Following the transaction, the vice president owned 22,002 shares in the company, valued at approximately $1,885,571.40. This trade represents a 4.43% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 67,804 shares of company stock valued at $5,711,242 in the last ninety days. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Up 0.7%

NYSE EW opened at $86.47 on Friday. The firm has a market cap of $50.22 billion, a PE ratio of 47.25, a price-to-earnings-growth ratio of 2.26 and a beta of 0.94. Edwards Lifesciences Corporation has a 52 week low of $65.94 and a 52 week high of $87.89. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06. The company has a 50 day moving average price of $82.74 and a 200 day moving average price of $81.25.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.04). Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The firm had revenue of $1.57 billion during the quarter, compared to analysts’ expectations of $1.54 billion. During the same period in the prior year, the firm posted $0.59 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 13.3% compared to the same quarter last year. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. As a group, sell-side analysts forecast that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.